Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Dual PPARgamma/RXRalpha activator as novel anti-breast cancer therapy

Award Number: R21CA181863
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2014
PERIOD OF PERFORMANCE END DATE: 11/30/2017

Group Awards By:

View Award Description

Dual PPARgamma/RXRalpha activator as novel anti-breast cancer therapy - ¿ DESCRIPTION (provided by applicant): Breast cancer (BCa) is a major health problem with a steady growth in new cases and deaths worldwide. Although more women are surviving cancer in recent years, mainly due to early detection and improved early stage therapies, most cancers eventually turn hormone-independent and metastatic disease requires simultaneous treatment with anti-hormonal and chemotherapeutic drugs. Therefore, novel strategies are still necessary for the prevention and treatment of BCa. PPAR¿ and RXR¿ are nuclear hormone receptors overexpressed in BCa and have been validated as ideal targets for the chemoprevention and treatment of BCa. A number of PPAR¿ and RXR¿ ligands have strong anticancer activity and have been studied with promising results in animal models. The combination of PPAR¿ and RXR¿ activators has synergistic effects in vitro and the antitumoral response is stronger than that of either ligand alone. The natural PPAR¿ ligand 15-delta- prostaglandin J2 (15¿PGJ2) is among the PPAR¿ agonists with strong growth inhibitory activity against cancer cells. Unfortunately, its mechanism of action has not been clearly defined most likely due to its high chemical reactivity which facilitates the interaction with numerous cellular targets. In our quest o find novel compounds with enhanced anti-tumoral properties and hopefully better therapeutic profiles, we have taken a medicinal chemistry approach to prepare a series of synthetic analogs of 15¿PGJ2 with improved chemical stability. The focus of this proposal is the characterization of one of these synthetic analogs, CPG-4109, which shows strong antiproliferative activity in BCa cells. This compound is unique because it activates both PPAR¿ and RXR¿ with similar efficacy. Like 15¿PGJ2, CPG-4109 also inhibits IKK2, a well-known therapeutic target in advanced BCa. Our working hypothesis is that activation of both PPAR¿ and RXR and the inhibition of IKK2 are the major actions required for optimal growth inhibitory activity of CPG-4109. Simultaneous activation of PPAR¿ and RXR mimics the synergistic effect observed when combining selective PPAR¿ and RXR ligands. We propose here to characterize the mechanism of action of CPG-4109 in BCa cells, with a special emphasis on the role of PPAR¿, RXR¿ and IKK2 on CPG-4109-mediated apoptosis. Additionally, in vivo studies will answer important questions regarding the bioavailability, toxicity, and antitumor efficacy of CPG-4109. Results of this project will reveal CPG-4109 as an excellent lead molecule for future optimization efforts directed to improve the potency and selectivity against most relevant targets in BCa. This novel compound represents a unique opportunity to develop novel multi-targeted drugs, with a wider spectrum of signal transduction modulation and probably improved efficacy, less toxicities, reduced risk of drug-drug interactions and better patient compliance adhering to a long term therapy program.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2016	TORREY PINES INSTITUTE FOR MOLECULAR STUDIES, INC.	3550 GENERAL ATOMICS CT	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	2	4/17/2018	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $237,510 )
2016	2016	TORREY PINES INSTITUTE FOR MOLECULAR STUDIES	3550 GENERAL ATOMICS COURT	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	001	2	2/15/2016	NON-COMPETING CONTINUATION	$23,751
2016	2016	TORREY PINES INSTITUTE FOR MOLECULAR STUDIES	3550 GENERAL ATOMICS COURT	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	2	11/17/2015	NON-COMPETING CONTINUATION	$213,759
														Subtotal = $237,510

Issue Date FY: 2015 ( Subtotal = $197,925 )
2015	2015	TORREY PINES INSTITUTE FOR MOLECULAR STUDIES	3550 GENERAL ATOMICS COURT	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	1	11/24/2014	NEW	$197,925
														Subtotal = $197,925

Grand Total All Awards = $435,435

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Dual PPARgamma/RXRalpha activator as novel anti-breast cancer therapy

Award Number: R21CA181863

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2014

PERIOD OF PERFORMANCE END DATE: 11/30/2017

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer